Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Developing novel therapies for cancer remains a significant challenge.
• Targeting tumor angiogenesis and metastasis is crucial for effective cancer treatment.

Purpose of the Study:

• To design and evaluate a novel fusion peptide (RK5) with dual targets for antitumor therapy.
• To assess the efficacy of RK5 in inhibiting tumor growth, metastasis, and improving survival.

Main Methods:

• Constructed and expressed a fusion peptide (RK5) comprising kringle 5 and a decapeptide in yeast.
• Evaluated RK5's effects on matrix metalloproteinase (MMP) activity, endothelial cell proliferation, and migration in vitro.
• Assessed RK5's impact on angiogenesis, tumor growth, metastasis, and survival in vivo using both protein and gene delivery methods.

Main Results:

• RK5 significantly inhibited MMP-9 activity, endothelial cell proliferation, and migration.
• RK5 demonstrated superior inhibitory effects compared to its individual components.
• In vivo studies showed RK5 inhibited angiogenesis, tumor growth, and metastasis, while increasing survival time.
• Both protein and gene delivery methods were effective for RK5 administration.

Conclusions:

• The fusion peptide RK5 exhibits potent antitumor activity by targeting multiple pathways.
• RK5 has potential for clinical application in cancer treatment due to its efficacy in inhibiting tumor growth and metastasis.
• This dual-target design offers a promising strategy for developing novel anticancer drugs.